Santa Ana Bio utilizes multi-omics platforms and antibody engineering to develop precision therapies for patients with autoimmune and inflammatory diseases. The company focuses on delivering targeted treatments that address the underlying immune mechanisms driving these conditions.
Funding
$203M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Autoimmune and inflammatory diseases are complex conditions driven by underlying immune mechanisms that are not always effectively addressed by current treatments. Existing therapies may lack precision, leading to off-target effects and suboptimal outcomes for patients.
Solution
Santa Ana Bio is developing precision therapies for autoimmune and inflammatory diseases by integrating multi-omics platforms with antibody engineering. This approach allows for the identification of specific immune drivers and the creation of targeted treatments designed to modulate these mechanisms. By focusing on the root causes of immune-mediated diseases, Santa Ana Bio aims to deliver more effective and personalized therapies.
Target Audience
The primary target audience includes patients with autoimmune and inflammatory diseases, as well as healthcare providers specializing in immunology and related fields.
Features
- Multi-omics platform for comprehensive immune profiling
- Antibody engineering capabilities for creating targeted therapeutics
- Focus on precision medicine for autoimmune and inflammatory diseases